Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
WEB4 days ago · Patients with newly diagnosed chronic myeloid leukemia (CML) need long-term therapy with high efficacy and safety. Asciminib, a BCR::ABL1 inhibitor specifically targeting the ABL myristoyl pocket ...
Asciminib safer and more effective than TKIs for CML patients
WEB20 hours ago · Asciminib appears to be a potentially safer and more effective treatment option than current standard of care TKI therapy for people with newly diagnosed chronic myeloid leukaemia, an Australian-led study shows.
Asciminib Shows Superior Efficacy vs Standard-of-Care Front ...
WEB4 days ago · Now, results are available from the phase III ASC4FIRST study (ClinicalTrials.gov identifier NCT04971226 ), which compared the efficacy of oral asciminib, a first-in-class allosteric inhibitor of BCR::ABL1, vs all current standard-of-care TKIs in patients with newly diagnosed CML. Findings from the trial showed that asciminib was …
Nature - Discovery of a novel BTK inhibitor S-016 and ...
WEB20 hours ago · Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas
CML: Asciminib First Line wirksamer als Standard ...
WEB1 day ago · Chicago – Bei Patienten mit neu diagnostizierter chronischer myeloischer Leukämie in der chronischen Phase (CML-CP) erreichte eine First-Line-Therapie mit dem STAMP-Tyrosinkinase-Inhibitor Asciminib im Vergleich zu einer Behandlung mit Standard-Tyrosinkinase-Inhibitor in Woche 48 mit 67,7% versus 49,0 % signifikant häufiger ein …
Suspending enzalutamide does not impact QOL in ...
WEB2 days ago · Suspension of treatment in patients with biochemically recurrent (BCR) nonmetastatic hormone-sensitive prostate cancer (nmHSPC) responding well to enzalutamide (Xtandi) regimens had no meaningful impact on patients’ global quality of life (QOL), according to a post-hoc analysis of the phase 3 EMBARK trial presented at the …
Sequential drug treatment targeting cell cycle and cell fate ...
WEB4 days ago · Background Targeted therapies exploiting vulnerabilities of cancer cells hold promise for improving patient outcome and reducing side-effects of chemotherapy. However, efficacy of precision therapies is limited in part because of tumor cell heterogeneity. A better mechanistic understanding of how drug effect is linked to cancer …
BCR: Inflación de mayo podría llegar al cero - El Men
WEB5 days ago · Julio Velarde, presidente del Banco Central de Reserva (BCR), proyectó que la tasa de inflación en mayo se situaría en niveles cercanos al 0%. Durante un evento organizado por un diario local, Velarde señaló que con las cifras de abril, que reflejaron una inflación anual del 2.4%, se espera un escenario de estabilidad para los próximos ...
South African Journal of Oncology
WEB4 days ago · Liu et al. 15 identified six predictive parameters for BCR following their report. For recurrence-free survival following radical prostatectomy, they asserted that SVI, PSM, ECE, LNI, and peri-neural invasion (PNI) were all statistically significant predictors ( …
WEB1 day ago · Conclusions : B pMRI could quantitively assess the zonal heterogeneity of PCa precisely and increase the predicting efficacy of HR patients , which can provide better help for clinical individualized treatment. Keywords: Prostate cancer; ISUP; MRI; Zonal heterogeneity. Introduction Prostate cancer (PCa) is the most frequently diagnosed and ...
Skip to content